Citigroup’s Damora Therapeutics DMRA Stock Holding History

Citigroup’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$337K	Sell	15,854 -27,565	-63%	-$779K	﹤0.01%	3965
2026 Q2	$1.13M	Buy	43,419 +32,324	+291%	+$783K	﹤0.01%	3355
2026 Q1	$287K	Buy	11,095 +9,968	+884%	+$256K	﹤0.01%	3815
2025 Q4	$25.9K	Buy	1,127 +1,084	+2,521%	+$18.8K	﹤0.01%	4797
2025 Q3	$160	Buy	+43	New	+$146	﹤0.01%	5779
2022 Q2	–	Sell	-10	Closed	-$1K	–	6384
2022 Q1	$1K	Hold	10	–	–	﹤0.01%	6165
2021 Q4	$1K	Hold	10	–	–	﹤0.01%	5762
2021 Q3	$1K	Hold	10	–	–	﹤0.01%	5696
2021 Q2	$1K	Buy	+10	New	+$1.36K	﹤0.01%	6032

Other funds holding DMRA

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Parkside Financial Bank & Trust Saint Louis, Missouri $1.51B AUM 17.86% 1-Year Est. Return

Citigroup's DMRA Position: Q3 2026 in Review

Citigroup reduced its Damora Therapeutics (DMRA) stake by 63% in Q3 2026, selling an estimated $779K and leaving 15,854 shares worth $337K. The position accounts for ﹤0.01% of the portfolio, ranked #3965.

Citigroup first reported a position in DMRA in Q2 2021 and has held it in 9 quarters since. The position peaked at $1.13M in Q2 2026. 21 funds tracked by Wall St. Rank hold DMRA as of Q3 2026.

Citigroup held 15,854 shares of Damora Therapeutics worth $337K as of Q3 2026.
Citigroup sold 27,565 Damora Therapeutics shares in Q3 2026, an estimated $779K.
Damora Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #3965 holding.
Citigroup first reported a position in Damora Therapeutics in Q2 2021 and has held it in 9 quarters since.
Citigroup's Damora Therapeutics position peaked at $1.13M in Q2 2026.
21 funds tracked by Wall St. Rank held Damora Therapeutics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.